Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients

April 9, 2008 updated by: Gilead Sciences

Phase IV, Open-Label, Randomized, Multicenter Study Evaluating Efficacy and Tolerability of Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir DF Compared to Unmodified HAART in HIV-1 Infected Subjects Who Have Achieved Virological Suppression on Their HAART Regimen

To compare the effectiveness (efficacy, safety & tolerability) of a Single Tablet Regimen of efavirenz/emtricitabine/tenofovir DF to subjects continuing on unmodified HAART as measured by the proportion of patients who maintain viral load (HIV-1 RNA) <200 copies/mL at Week 48.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Anticipated)

300

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Ponce, Puerto Rico, 00731
      • San Juan, Puerto Rico, 00909
    • Alabama
      • Hobson City, Alabama, United States, 36201
    • Arizona
      • Phoenix, Arizona, United States, 85006
    • California
      • Beverly HIlls, California, United States, 90211
      • Long Beach, California, United States, 90813
      • Los Angeles, California, United States, 90069
      • Oakland, California, United States, 94609
      • San Diego, California, United States, 92103
      • San Francisco, California, United States, 94114
      • Tarzana, California, United States, 91356
    • Colorado
      • Denver, Colorado, United States, 80220
    • Connecticut
      • Norwalk, Connecticut, United States, 06851
    • District of Columbia
      • Washington, District of Columbia, United States, 20037
    • Florida
      • Ft. Lauderdale, Florida, United States, 33308
      • Hollywood, Florida, United States, 33020
      • Miami, Florida, United States, 33136
      • Orlando, Florida, United States, 32803
      • Pensacola, Florida, United States, 32504
      • Port St Lucie, Florida, United States, 34952
      • Safety Harbor, Florida, United States, 34695
      • Tampa, Florida, United States, 33607
      • Vero Beach, Florida, United States, 32960
    • Georgia
      • Atlanta, Georgia, United States, 30312
      • Decatur, Georgia, United States, 30033
    • Illinois
      • Aurora, Illinois, United States, 60505
      • Chicago, Illinois, United States, 60657
    • Indiana
      • Indianapolis, Indiana, United States, 46280
    • Maryland
      • Baltimore, Maryland, United States, 21201
    • Massachusetts
      • Boston, Massachusetts, United States, 02030
      • Springfield, Massachusetts, United States, 01107
    • Michigan
      • Berkley, Michigan, United States, 48072
      • Grosse Pointe Woods, Michigan, United States, 48236
    • Minnesota
      • Minneapolis, Minnesota, United States, 55404
    • Missouri
      • St. Louis, Missouri, United States, 63139
    • New Jersey
      • Hillsborough, New Jersey, United States, 08844
      • Newark, New Jersey, United States, 07102
      • Newark, New Jersey, United States, 07101
      • Somers Point, New Jersey, United States, 08244
    • New York
      • Albany, New York, United States, 12208
      • Brooklyn, New York, United States, 11203
      • Mount Vernon, New York, United States, 10550
      • New York, New York, United States, 10011
      • Rochester, New York, United States, 14604
    • North Carolina
      • Charlotte, North Carolina, United States, 28209
      • Greenville, North Carolina, United States, 27858
      • Winston-Salem, North Carolina, United States, 27157
    • Ohio
      • Akron, Ohio, United States, 44304
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
    • Rhode Island
      • Providence, Rhode Island, United States, 02906
    • Texas
      • Dallas, Texas, United States, 75204
      • Harlingen, Texas, United States, 78550
      • Houston, Texas, United States, 77009
    • Virginia
      • Annandale, Virginia, United States, 22003
      • Hampton, Virginia, United States, 23666
    • Washington
      • Spokane, Washington, United States, 99204

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • HIV-1 positive patients who have maintained an HIV-1 viral load <200 copies/mL, for at least 3 months.
  • Patients must be on their first HAART or have documented viral suppression on a PI-based regimen at the time of any prior change in therapy.
  • HAART must consist of either:

    1. A PI (with or without ritonavir) + at least 2 NRTIs or
    2. An NNRTI + at least 2 NRTIs.
  • Negative serum pregnancy test.

Exclusion Criteria:

  • Patients who have taken any NNRTI prior to their current therapy.
  • Patients who have taken a NRTI-only therapy for greater than 7 days prior to their current therapy.
  • Patients who are currently taking EFV+FTC+TDF.
  • Patients who have a creatinine clearance of <60 mL/min by Cockcroft-Gault estimation.
  • Patients who have experienced virologic failure with any previous ARV therapy.
  • Patients who have documented resistance to any of the study agents at any time in the past.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Primary: Proportion of patients with HIV-1 RNA levels <200 copies/mL at Week 48
Safety Outcome Measures: Adverse Events, Laboratory Tests
Outcomes Research Measures: Quality of life, adherence, preference of medication, perceived ease of regimen, HIV symptoms

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Study Director: John Flaherty, Gilead Sciences

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2006

Primary Completion (Actual)

October 1, 2007

Study Completion (Actual)

January 1, 2008

Study Registration Dates

First Submitted

August 16, 2006

First Submitted That Met QC Criteria

August 16, 2006

First Posted (Estimate)

August 17, 2006

Study Record Updates

Last Update Posted (Estimate)

April 10, 2008

Last Update Submitted That Met QC Criteria

April 9, 2008

Last Verified

April 1, 2008

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe